非酒精性脂肪性肝病合并2型糖尿病患者尿微量白蛋白及血清糖化血红蛋白和甲状腺激素水平变化*

doi:10.3969/j.issn.1672-5069.2025.02.013

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者尿微量白蛋白(U-mAl)及血清糖化血红蛋白(HbA1c)和甲状腺激素水平变化。方法 2019年1月～2024年1月我院收治的T2DM患者91例和同期收治的NAFLD合并T2MD患者91例,使用全自动免疫分析仪检测血清促甲状腺素(TSH)、四碘甲状腺原氨酸(T4)和FT4水平,常规检测U-mAl)及HbA1c和血清胰岛素(FINS)水平,计算HOMA-IR。结果 NAFLD合并T2DM患者空腹血糖(FBG)、血清FINS、HOMA-IR和血清HbAlC水平分别为(7.6±1.0)mmol/L、(12.6±2.7)μIU/mL、(4.3±1.1)和(8.2±0.9)%,均显著高于T2DM患者【分别为(7.1±1.3)mmol/L、(9.4±3.1)μIU/mL、(3.0±1.3)和(7.0±1.2)%,P＜0.05】;NAFLD合并T2DM患者U-mAl和血清T4水平分别为(71.6±10.1)mg/L和(134.7±16.6)nmol/L,显著高于T2DM患者【分别为(40.2±10.8)mg/L和(119.0±14.9)nmol/L,P＜0.05】,而血清TSH和FT4水平分别为(2.1±0.7)mU/L和(12.4±1.7)pmol/L,均显著低于T2DM患者【分别为(3.5±0.7)mU/L和(16.8±3.0)pmol/L,P＜0.05】;两组血脂水平无显著性差异(P>0.05)。结论 NAFLD合并T2DM患者U-mAl和血清甲状腺素水平可能升高,提示临床处理的复杂性,需引起足够的重视。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 尿微量白蛋白, 甲状腺激素

Abstract: Objective The aim of this study was to investigate changes of urine microalbumin(U-mAl), serum hemoglobin Alc (HbA1c) and thyroid hormones in patients with non-alcoholic fatty liver disease (NAFLD) and concomitant type 2 diabetes mellitus (T2DM). Methods 91 patients with NAFLD and T2DM [non-alcoholic fatty liver (NAFL) in 56 cases,non-alcoholic steatohepatitis (NASH) in 23 cases and cirrhosis in 12 cases] and 91 patients with T2DM were encountered in our hospital between January 2019 and January 2024, serum thyroid stimulating hormone (TSH), tetraiodothyronine(T4) and FT4 levels were assayed by RIA, and fasting blood glucose (FBG), HbAlC, fasting insulin(FINS) and U-mAllevel were routinely detected. Results FBG, serum FINS, HOMA-IR and HbAlC levels in patients with NAFLD and T2DM were (7.6±1.0)mmol/L, (12.6±2.7)μIU/mL, (4.3±1.1) and (8.2±0.9)%, all much higher than [(7.1±1.3)mmol/L, (9.4±3.1)μIU/mL, (3.0±1.3) and (7.0±1.2)%, respectively, P＜0.05] in patients with T2DM; U-mAl and serum T4 levels in patients with NAFLD and T2DMwere(71.6±10.1)mg/L and (134.7±16.6)nmol/L, both significantly higher than [(40.2±10.8)mg/L and (119.0±14.9)nmol/L, P＜0.05], while serum TSH and FT4 were (2.1±0.7)mU/L and (12.4±1.7)pmol/L, both significantly lower than [(3.5±0.7)mU/L and (16.8±3.0)pmol/L, P＜0.05] in patients with T2DM; there were no significant differences as respect to serum fat levels between the two groups (P>0.05). Conclusion U-mAl and serum thyroid hormone levels in patients with NAFLD and concomitant T2DM could elevate, which might sophisticate clinical management in this circumstances.

Key words: Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Urine microalbumin, Hemoglobin Alc, Thyroid hormone

吴彬彬, 李丹丹, 王子铭. 非酒精性脂肪性肝病合并2型糖尿病患者尿微量白蛋白及血清糖化血红蛋白和甲状腺激素水平变化^*[J]. 实用肝脏病杂志, 2025, 28(2): 210-213.

Wu Binbin, Li Dandan, Wang Ziming. Changes of urine microalbumin and serum thyroid hormones in patients with non-alcoholic fatty liver disease and concomitant type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2025, 28(2): 210-213.

参考文献

[1] Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin NorthAm,2021,50(3):337-355.
[2] Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord,2022,22(1):63.
[3] 叶晓贤,杨丽,雷丽. 血清糖化血红蛋白和IL-6对NAFLD发病风险的预测价值探讨. 实用肝脏病杂志,2020,23(2):199-202.
[4] Vidal-Cevallos P, Murúa-Beltrán Gall S, Uribe M, et al. Understanding the relationship between nonalcoholic fatty liver disease and thyroid disease. Int J Mol Sci,2023,24(19):14605.
[5] Fan H, Liu Z, Zhang X, et al. Thyroidstimulating hormone levels are associated with genetically predicted nonalcoholic fatty liver disease. J Clin Endocrinol Metab,2022,107(9):2522-2529.
[6] Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev,2019,35(6):3158,e6.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. NAFLD防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-18.
[8] Tangelloju S, Little BB, Esterhay RJ, et al. Type 2 diabetes mellitus (T2DM) "Remission" in non-bariatric patients 65 years and older. FrontPublic Health,2019,7(1):82.
[9] Hubacek JA, Dlouha L, Adamkova V, et al. Genetic risk score is associated with T2DM and diabetes complications risks. Gene,2023,849(1):146921.
[10] Rojas YAO, Cuellar CLV, Barrón KMA, et al. Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. Ann Hepatol,2022,27(6):100706.
[11] Lee BW, Lee YH, Park CY,et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the fatty liver research group of the Korean diabetes association. Diabetes Metab J,2020,44(3):382-401.
[12] Ampuero J, Aller R, Gallego-Durán R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol,2020,73(1):17-25.
[13] Thibaut R, Gage MC, Pineda-Torra I, et al. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J,2022,289(11):3024-3057.
[14] 丁晓洁,张永明,宋海燕,等. NAFLD合并T2DMNLR和PLR变化及其临床意义探讨. 实用肝脏病杂志,2023,26(6):815-818.
[15] Frankowski R, Kobierecki M, Wittczak A, et al. Type 2 diabetes mellitus, non-alcoholic fatty liver disease, and metabolic repercussions: the vicious cycle and its interplay with inflammation. Int J Mol Sci,2023,24(11):9677.
[16] Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol,2024,22(10):1999-2010.
[17] Bovolini A, Garcia J, Andrade MA, et al. Metabolic syndrome pathophysiology and predisposing factors. Int J Sports Med,2021,42(3):199-214.
[18] Koohi F, Ahmadi N, Azizi F, et al. Patterns of change in obesity indices and other cardiometabolic risk factors before the diagnosis of type 2 diabetes: two decades follow-up of the Tehran lipid and glucose study. J Transl Med,2022,20(1):518.
[19] Chao HW, Chao SW, Lin H, et al. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int J Mol Sci,2019,20(2):298.
[20] Gaeini Z, Bahadoran Z, Mirmiran P,et al. Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study. BMC Endocr Disord,2022,22(1):59.
[21] Xing Y, Zhen Y, Yang L, et al. Association between hemoglobin glycation index and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne),2023,14:1094101.
[22] Xie Y, Kong W, Wang X,et al. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord,2022,22(1):220.
[23] Tahara K, Akahane T, Namisaki T, et al. Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver disease. JGH Open,2019,4(3):400-404.
[24] Caussy C. Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment? Diabetes Metab,2020,46(4):259-260.
[25] Kim HJ. Importance of thyroid-stimulating hormone levels in liver disease. J Pediatr Endocrinol Metab,2020,33(9):1133-1137.

非酒精性脂肪性肝病合并2型糖尿病患者尿微量白蛋白及血清糖化血红蛋白和甲状腺激素水平变化^*

Changes of urine microalbumin and serum thyroid hormones in patients with non-alcoholic fatty liver disease and concomitant type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王小燕, 崔文星, 陈超. FibroTouch^©和CT定量检查诊断脂肪肝人群NASH效能研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 198-201.
[2]	韩悦, 翟菲菲, 张晴, 孟慧敏. 超声衰减成像系数诊断非酒精性脂肪性肝病患者肝脏脂肪变性程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 202-205.
[3]	钱平安, 姜煜资, 聂红明. 穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 206-209.
[4]	苏雅, 王炳元. 酒精性肝病不是代谢相关性脂肪性肝病[J]. 实用肝脏病杂志, 2025, 28(1): 5-8.
[5]	马敏, 许巧云. 非酒精性脂肪性肝病患者血清Arg-1水平和ApoB/ApoA1比值变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 52-55.
[6]	郑慧慧, 王玉蓉, 宰国田. 非酒精性脂肪性肝病合并颈动脉粥样硬化斑块患者血清IL-17、IFN-γ和IL-6变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 56-59.
[7]	沈玥, 朱宁, 王海. FibroTouch检测参数诊断非酒精性脂肪性肝炎患者效能分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 60-63.
[8]	贾纪会, 张译之, 林静, 兰佳庆, 陈煜, 段钟平, 张晓慧. 柚皮苷调节NAFLD小鼠脂代谢紊乱机制研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 816-819.
[9]	伊芬秀, 伊芬锦, 娄仲雷. 2型糖尿病合并细菌性肝脓肿患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 935-938.
[10]	贾双珍, 吴天威, 吴捷. microRNA-122与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 646-649.
[11]	李艳敏, 张维, 胡彦彦, 齐蕾. 老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 697-700.
[12]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[13]	李开楊, 赵琦, 黄敬, 唐云, 蔺晓源, 刘杰民, 杨梅. 中国临床试验注册中心注册的非酒精性脂肪性肝病临床试验特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 531-534.
[14]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.
[15]	孙世磊, 刘翠翠, 李曙光, 鲁科翔. 非酒精性脂肪性肝病合并T2DM患者血清成纤维细胞生长因子-21和分泌型卷曲相关蛋白5水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 357-360.